Long-term real-world persistence of guselkumab in patients with moderate-to-severe psoriasis J. Borrás-Blasco, R. Alcala, A. Valcuende-Rosique, S. Cornejo

Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time J.M. Carrascosa, N. Rivera, I. Garcia-Doval, G. Carretero, F. Vanaclocha, E. Daudén, F.J. Gómez-García, P. De-la-Cueva-Dobao, E. Herrera-Ceballos, I. Belinchón, M. Alsina, J.L. Sánchez-Carazo, M. Ferrán, J.L. Lopez-Estebaranz, B. Pérez-Zafrilla, M. Llamas, R. Rivera, C. Ferrándiz

Combined Biologic Therapy in 2 Patients With Severe Psoriasis and Severe Atopic Dermatitis M. Pascual Ares, A. Orbea Sopeña, A. Aramburu González, J. Gardeazábal García